Atovaquone

Drug Profile

Atovaquone

Alternative Names: 566C; 566C80; BW 566C; BW A566C; BW A566C80; Mepron; Mepron Suspension; Samtirel; Wellvole; Wellvone

Latest Information Update: 26 Apr 2012

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiprotozoals; Naphthoquinones
  • Mechanism of Action Electron transport complex I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Pneumocystis pneumonia
  • Discontinued Malaria; Toxoplasmosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 17 Apr 2012 Launched for Pneumocystis pneumonia (treatment and prevention) in Japan (PO; suspension)
  • 18 Jan 2012 Registered for Pneumocystis pneumonia (treatment and prevention) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top